Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

757 results about "As Directed" patented technology

Indicates that a drug or therapy should be used as specified by the prescribing physician.

Task distribution processing system and the method for subscribing computers to perform computing tasks during idle time

A computer executable "aggregate" task is processed by dividing it into subtasks and distributing the subtasks "on demand" to remotely located subscribing computers via a computer network. The aggregate task originates at a coordinating computer, coupled to one or more peripheral computers by appropriate communications links. The coordinating computer divides the aggregate task into multiple independent subtasks. Each peripheral computer begins to "subscribe" to the coordinating computer's aggregate task by obtaining an "idle time activation program" from the coordinating computer, and then installing the program locally. The idle time activation program which may include a screen saver, activates automatically when the subscribing computer is inactive. Continuing the subscription process, each peripheral computer requests a subtask from the coordinating computer. In response, the coordinating computer distributes different subtasks among the subscribing computers, completing the subscription process. The subscribing computers automatically work on their respective subtasks whenever they are idle, as directed by the local idle time activation program. When a subscribing computer completes its subtask, it transmits results back to the coordinating computer. When results of all subtasks have been received from subscribing computers, the coordinating computer compiles and stores these results, concluding the aggregate task.
Owner:IBM CORP

Linear lighting apparatus and methods

Linear lighting systems and methods. In one example, two or more lighting elements having an essentially linear or curvilinear shape are coupled together to form a lighting system. Each lighting element includes a group of LEDs arranged so as to illuminate the essentially linear or curvilinear shape of the lighting element. Each element may include LEDs to generate the same color light, and/or LEDs to generate light of different colors. Additionally, each element may include one or more controllers to control the LEDs so as to create a variety of temporal and/or color-oriented lighting effects. The controller(s) may employ one or more of a variety of control techniques to control the LEDs, such as those involving analog control signals or pulse-width modulated (PWM) control signals. The lighting elements of the system may each be configured as a “stand alone” unit working within the system, producing respective lighting effects that may or may not be coordinated with each other. Alternatively, two or more elements of the system may be configured as addressable lighting elements to facilitate coordination of the elements as a networked lighting system. Any of the foregoing linear lighting systems may be used in a variety of interior or exterior, as well as direct or indirect, lighting applications. In one example, such lighting systems are particularly well-suited as replacements or substitutes for neon lighting installations.
Owner:PHILIPS LIGHTING NORTH AMERICA CORPORATION

Abuse-deterrent drug formulations

An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.
Owner:COLLEGIUM PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products